Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 1:00 PM ET

Healthcare Equipment and Supplies

Company Overview of Bioness Inc.

Company Overview

Bioness Inc. designs, develops, and distributes medical devices for people with stroke, multiple sclerosis, traumatic brain injury, cerebral palsy, and spinal cord injury. It offers L300, a foot drop system for people with various neurological conditions; L300 Plus for foot drop and thigh weakness, which delivers programmed, low-level electrical stimulation to activate the nerves controlling the muscles of the leg; H200, a wireless hand rehabilitation system for reaching, grasping, opening, and closing the hand; and StimRouter, an implantable neuromodulation device designed to treat intractable pain of peripheral nerve origin. The company also offers StimRouter, an implantable neuromodulatio...

25103 Rye Canyon Loop

Valencia, CA 91355

United States

Founded in 2004





Key Executives for Bioness Inc.

Chief Executive Officer and President
Founder and Chairman
Age: 89
Compensation as of Fiscal Year 2015.

Bioness Inc. Key Developments

Bioness Announces the Publication of Stimrouter Neuromodulation System Clinical Trial Results

Bioness Inc. announced the successful results from the company's 1-year clinical trial of the StimRouter Neuromodulation System. The results have been published in the January issue of Neuromodulation. The prospective, multi-center, randomized, double blinded, partial crossover study assessed safety and efficacy of the StimRouter Neuromodulation System for the treatment of patients with chronic pain of peripheral nerve origin. The StimRouter Treatment Group achieved primary endpoints of efficacy and safety and demonstrated a statistically significant (p<0.0001) improvement in pain reduction as compared to the control group. StimRouter received clearance from the Food and Drug Administration (FDA) last year and is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy. StimRouter is the only implantable neuromodulation device indicated and marketed to treat chronic pain of peripheral nerve origin. Unlike traditional pain management neuromodulation devices (e.g. spinal cord stimulators), StimRouter requires no trial lead, is minimally invasive and performed under local anesthesia. As a potential cost-effective alternative to injections, ongoing medication regimens and complex surgeries, StimRouter is enabling underserved patient populations to access neuromodulation technology to treat chronic pain.

Bioness Inc. Announces the Commercial Availability of StimRouter Neuromodulation System at International Neuromodulation Society World Congress

On June 8, 2015, at the International Neuromodulation Society 12th World Congress, Bioness Inc. announced the commercial availability of StimRouter, an implantable neuromodulation device to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy. StimRouter received clearance from the United States Food and Drug Administration (FDA) in February and is the only implantable neuromodulation device indicated to treat chronic pain of peripheral nerve origin. StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. Each system is programmed at the direction of the physician to meet patient requirements.

Bioness, Inc. Announces Strategic Business Partnership with the American Physical Therapy Association

Bioness Inc. announced that it has been named as a Strategic Business Partner by the American Physical Therapy Association (APTA). Bioness joins a select roster of other companies from the therapeutic device and medical device and services industries that work with APTA to promote evidence-based innovations and expand access to therapy. This partnership is a unique opportunity for Bioness to generate awareness and offer rehabilitation solutions to the 76,000 well-informed and influential current APTA members.

Similar Private Companies By Industry

Company Name Region
Veran Medical Technologies, Inc. United States
Harvard Apparatus, Inc. United States
Correx, Inc. United States
TCGRx United States
Breg, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bioness Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at